Assessment of the quality of life of patients with inflammatory bowel diseases depending on the drug therapy performed

This paper details the impact of inflammatory bowel disease (IBD) on patients’ quality of life. In order to assess patients’ quality of life, a number of specific and general tools have been developed to assess quality of life in patients with IBS. According to the data obtained in a number of clinical studies, IBS significantly reduces the quality of life of patients compared to healthy people. Moreover, the quality of life is directly related to the form and degree of ICD activity. Thus, worse quality of life is associated with Crohn’s disease and active stage of the disease. However, in the remission stage, the quality of life in patients with Crohn’s disease (CD) and ulcerative colitis (UC) do not have statistically significant differences. In addition, diet and lifestyle are of great importance for the QOL of patients with UC. Conservative therapy is an extremely important link that allows to significantly improve the life quality of patients, in which targeting pre-drugs play an important role. The latter significantly improve the QOL of patients with ICD, contributing to the transition of ICD from the active form to remission.

inflammatory bowel diseases, quality of life, Crohn’s disease, ulcerative colitis, drug therapy of ICDs

1. Bao S., Liu W., Liu L., Jiang G., Chen H. Analysis of Factors Related to Spiritual Psychology and Quality of Life in Patients with Inflammatory Bowel Disease Based on Artificial Intelligence IBD Nursing Technology. J Healthc Eng. 2022 Apr 11;2022:7702432. doi: 10.1155/2022/7702432.

2. Schliep M., Chudy-Onwugaje K., Abutaleb A., Langenberg P., Regueiro M., Schwartz D. A. et al. TELEmedicine for Patients With Inflammatory Bowel Disease (TELE-IBD) Does Not Improve Depressive Symptoms or General Quality of Life Compared With Standard Care at Tertiary Referral Centers. Crohns Colitis 360. 2020 Jan;2(1): otaa002. doi: 10.1093/crocol/otaa002.

3. Navas-López V.M., Martel L. C., Martín-Masot R., Rubio M. N., Santana N. R., López M. H. et al. The Effect of the Inflammatory Bowel Disease Classroom in Nature on the Quality of Life of Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2020 Aug;71(2):243-245. doi: 10.1097/MPG.0000000000002746.

4. Roukas C., Miller L., Hamborg T., Gordeev V., Lindsay J., Norton C. et al. DOP23 Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST survey. Journal of Crohn’s and Colitis. 2023;17: i87-i88. doi: 10.1093/ecco-jcc/jjac190.0063.

5. Calviño-Suárez C., Ferreiro-Iglesias R., Bastón-Rey I., Barreiro-de Acosta M. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment.Int J Environ Res Public Health. 2021 Jul 4;18(13):7159. doi: 10.3390/ijerph18137159.

6. Chen X.L., Zhong L. H., Wen Y., Liu T. W., Li X. Y., Hou Z. K. et al. Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties. Health Qual Life Outcomes. 2017 Sep 15;15(1):177. doi: 10.1186/s12955-017-0753-2.

7. van Andel E. M., Koopmann B. D.M., Crouwel F., Noomen C. G., de Boer N. K.H., van Asseldonk D. P. et al. Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure? J Crohns Colitis. 2020 Sep 16;14(9):1299-1315. doi: 10.1093/ecco-jcc/jjaa057.

8. Yarlas A., Maher S., Bayliss M., Lovley A., Cappelleri J. C., Bushmakin A. G. et al. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev. 2020 Apr 27;7(2):189-205. doi: 10.17294/2330-0698.1722.

9. Wilburn J., McKenna S.P., Twiss J., Kemp K., Campbell S. Assessing quality of life in Crohn’s disease: development and validation of the Crohn’s Life Impact Questionnaire (CLIQ). Qual Life Res. 2015 Sep;24(9):2279-88. doi: 10.1007/s11136-015-0947-1.

10. Adegbola S.O., Dibley L., Sahnan K., Wade T., Verjee A., Sawyer R. et al. Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale. Gut. 2021 Sep;70(9):1649-1656. doi: 10.1136/gutjnl-2019-320553.

11. Haraldstad K., Wahl A., Andenæs R., Andersen J. R., Andersen M. H., Beisland E. et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019 Oct;28(10):2641-2650. doi: 10.1007/s11136-019-02214-9.

12. Knowles S.R., Graff L. A., Wilding H., Hewitt C., Keefer L., Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I. Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751. doi: 10.1093/ibd/izx100. PMID: 29562277.

13. Faus A.L., Turchi R. M., Polansky M., Berez A., Leibowitz K. L. Health-Related Quality of Life in Overweight/Obese Children Compared With Children With Inflammatory Bowel Disease. Clin Pediatr (Phila). 2015 Jul;54(8):775-82. doi: 10.1177/0009922814562555.

14. Knowles S.R., Keefer L., Wilding H., Hewitt C., Graff L. A., Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part II. Inflamm Bowel Dis. 2018 Apr 23;24(5):966-976. doi: 10.1093/ibd/izy015.

15. Abdovic S., Mocic Pavic A., Milosevic M., Persic M., Senecic-Cala I., Kolacek S. The IMPACT-III (HR) questionnaire: a valid measure of health-related quality of life in Croatian children with inflammatory bowel disease. J Crohns Colitis. 2013 Dec;7(11):908-15. doi: 10.1016/j.crohns.2012.12.010.

16. Zhang C.K., Hewett J., Hemming J., Grant T., Zhao H., Abraham C. et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jul;19(8):1732-9. doi: 10.1097/MIB.0b013e318281f395.

17. Pueschel L., Kockelmann F., Kueck M., Tegtbur U., Seidler U., Lenzen H. et al. P545 Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases. Journal of Crohn’s and Colitis. 2023;17: i671-i672. doi: 10.1093/ecco-jcc/jjac190.0675.

18. Joseph Rogers, Brittany Rogers. A diet and lifestyle-factor intervention program to improve nutritional status, symptoms, and quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2023.29(1): S15. doi: 10.1093/ibd/izac247.030.

19. Scheffers L.E., Vos I. K., Utens E. M.W.J., Dieleman G. C., Walet S., Escher J. C. et al. Physical Training and Healthy Diet Improved Bowel Symptoms, Quality of Life, and Fatigue in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023 Aug 1;77(2):214-221. doi: 10.1097/MPG.0000000000003816.

20. Bastida G., Nos P., Aguas M., Beltrán B., Iborra M., Ortiz V. et al. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010 Mar 2;10:26. doi: 10.1186/1471-230X-10-26.

21. Calvet X., Gallardo O., Coronas R., Casellas F., Montserrat A., Torrejón A. et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn’s disease. Inflamm Bowel Dis. 2006 Aug;12(8):692-6. doi: 10.1097/00054725-200608000-00004.

22. Alruthia Y., Alsharif W., Almuaythir G., Alrasheed H., Alharbi O., Azzam N. et al. P444 The impact of azathioprine on inflammatory bowel disease patients’ overall health-related quality of life: A single-centre retrospective cohort study. Journal of Crohn’s and Colitis. 2020;14(1): S400-S401. doi: 10.1093/ecco-jcc/jjz203.573.

23. Feagan B.G., Reinisch W., Rutgeerts P., Sandborn W. J., Yan S., Eisenberg D. et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr;102(4):794-802. doi: 10.1111/j.1572-0241.2007.01094.x.

24. Silva R.P.L., Baima J. P., Bissoli G. C., Farinelli E., Sibia C. F., Barros J. R. et al. N816 Anti-TNF therapy improves the quality of life in patients with ulcerative colitis, Journal of Crohn’s and Colitis. 2017;11: S498-S499. doi: 10.1093/ecco-jcc/jjx002.940.

25. Feagan B.G., Yan S., Bala M., Bao W., Lichtenstein G. R. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003 Oct;98(10):2232-8. doi: 10.1111/j.1572-0241.2003.07674.x.

26. Herrera-de Guise C., Casellas F., Robles V., Navarro E., Borruel N. Predictive value of early restoration of quality of life in Crohn’s disease patients receiving antitumor necrosis factor agents. J Gastroenterol Hepatol. 2015 Feb;30(2):286-91. doi: 10.1111/jgh.12803.

27. Travis S., Feagan B. G., Peyrin-Biroulet L., Panaccione R., Danese S., Lazar A. et al. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27;11(11):1317-1325. doi: 10.1093/ecco-jcc/jjx093.

28. Louis E., Löfberg R., Reinisch W., Camez A., Yang M., Pollack P. F. et al. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn’s disease: results from the CARE trial. J Crohns Colitis. 2013 Feb;7(1):34-43. doi: 10.1016/j.crohns.2012.02.017.

29. Saro C., Ceballos D., Muñoz F., de la Coba C., Aguilar M. D., Lázaro P. et al. Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab. Rev Esp Enferm Dig. 2017 Feb;109(2):122-129. doi: 10.17235/reed.2016.4600/2016.

30. Feagan B., Gibson P., Marano C., Strauss R., Han C., Johanns J. et al. P225 Impact of subcutaneously administered golimumab on disease specific and generic health-related quality of life in patients with moderately to severely active ulcerative colitis: Results from PURSUIT-SC induction. Journal of Crohn’s and Colitis. 2013;7(1): S99-S100. doi: 10.1016/S1873-9946(13)60247-0.

31. Feagan B.G., Patel H., Colombel J. F., Rubin D. T., James A., Mody R. et al. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 Jan;45(2):264-275. doi: 10.1111/apt.13852.

32. Barnes E., Hanson J., Regueiro M., Saha S., Sands B. E., Rubin D. et al. DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort. Journal of Crohn’s and Colitis. 2020;14(1): S063-S063. doi: 10.1093/ecco-jcc/jjz203.064.

33. Vermeire S., Loftus E. V. Jr., Colombel J. F., Feagan B. G., Sandborn W. J., Sands B. E. et al. Long-term Efficacy of Vedolizumab for Crohn’s Disease. J Crohns Colitis. 2017 Apr 1;11(4):412-424. doi: 10.1093/ecco-jcc/jjw176.

34. Parkes G., Akbar A., Beales I., Buckley M., Creed T., Din S. et al. P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn’s disease in the UK and Ireland: OCTAVO cohort 2. Journal of Crohn’s and Colitis. 2020;14(1): S575-S576. doi: 10.1093/ecco-jcc/jjz203.841.

35. Eriksson C., Rundquist S., Lykiardopoulos V., Karlén P., Grip O., Söderman C. et al. P758 Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn’s disease (SVEAH CD). Journal of Crohn’s and Colitis. 2018;12(1): S494-S495. doi: 10.1093/ecco-jcc/jjx180.885.

36. Sands B.E., Sandborn W. J., Panaccione R., O’Brien C.D., Zhang H., Johanns J. et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.

37. Sandborn W.J., Rowbotham D. S., Leong R. W.L., Han C., Zhou Y., Zhang H. et al. DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension. Journal of Crohn’s and Colitis. 2020;14(1): S094-S095. doi: 10.1093/ecco-jcc/jjz203.095.

38. Sands B.E., Han C., Gasink C., Jacobstein D., Szapary P., Gao L. L. et al. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease. J CrohnsColitis. 2018 Jul 30;12(8):883-895. doi: 10.1093/ecco-jcc/jjy055.

39. Marquès-Camí M., Robles Alonso V., Borruel N., Herrera de Guise C., Mayorga L., Casellas F. Normalization of long-term quality of life in Crohn’s disease patients receiving ustekinumab. Rev Esp Enferm Dig. 2021 May;113(5):313-317. doi: 10.17235/reed.2020.6941/2020.

40. Adis Editorial. Tofacitinib. Drugs R D. 2010;10(4):271-84. doi: 10.2165/11588080-000000000-00000.

41. Ghoreschi K., Jesson M. I., Li X., Lee J. L., Ghosh S., Alsup J. W. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668.

42. FDA approves new treatment for moderately to severely active ulcerative colitis. 2018. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-moderately-severely-active-ulcerative-colitis.

43. Panés J., Vermeire S., Lindsay J. O., Sands B. E., Su C., Friedman G. et al. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133.

44. Davies S. C., Hussein I. M., Nguyen T. M., Parker C. E., Khanna R., Jairath V. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020 Jan 27;1(1): CD012381. doi: 10.1002/14651858.CD012381.pub2.

45. Probert C. S., Dignass A. U., Lindgren S., Oudkerk Pool M., Marteau P.Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 2014 Mar;8(3):200-7. doi: 10.1016/j.crohns.2013.08.007.

46. Bastida G., Nos P., Aguas M., Beltrán B., Iborra M., Ortiz V. et al. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010 Mar 2;10:26. doi: 10.1186/1471-230X-10-26.

47. Calvet X., Gallardo O., Coronas R., Casellas F., Montserrat A., Torrejón A. et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn’s disease. Inflamm Bowel Dis. 2006 Aug;12(8):692-6. doi: 10.1097/00054725-200608000-00004.